Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral difelikefalin for moderate-to-severe pruritus in notalgia paresthetica
2023-503957-36-00Phase 3Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Dec 2023
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in notalgia paresthetica (NP) comparing Difelikefalin with Placebo (2 arms). Primary endpoints: Responder rate with ≥4-point improvement in itch, Complete or near-complete itch relief at Week 8 and 3 more. Started Dec 2023; status: completed.
02
Drugs
difelikefalin
03
Conditions
notalgia paresthetica (NP)
Beyond the preview
Go deeper on 2023-503957-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503957-36-00.